Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME321B)

Drug Name

VX-944 Drug Info

Synonyms

AVN-944; AVN944; 297730-17-7; AVN 944; UNII-I3NPL1V48Q; I3NPL1V48Q; 501345-02-4; VX 944; SCHEMBL19784823; CHEMBL3349001; DTXSID80183921; EX-A778; AOB5557; ZINC3963015; AKOS027340045; CS-3427; NCGC00345803-01; NCGC00345803-05; HY-13560; AS-16899; SC-82478; (R)-1-cyanobutan-2-yl ((S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethyl)carbamate; Carbamic acid, ((1S)-1-(3-((((3-methoxy-4-(5- oxazolyl)phenyl)amino)carbonyl)amino)phenyl)ethyl)-, (1R)-1-(cyanomethyl)propyl ester; (2R)-1-cyanobutan-2-yl N-[(1S)-1-[3-({[3-metho

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 9918559
CAS Number: CAS 297730-17-7
TTD Drug ID: DME321B

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Inosine-5'-monophosphate dehydrogenase (IMPDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thioguanine	DM7NKEV	Acute lymphocytic leukaemia	2B33.3	Approved	[4]
Enteric-coated mycophenolate sodium	DMK659W	Transplant rejection	NE84	Approved	[5]
IMS	DMFACQU	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[6]
R-1518	DM2J5AO	Hepatitis C virus infection	1E51.1	Discontinued in Phase 1	[7]
EPB-415	DMBLSX3	Hepatitis C virus infection	1E51.1	Investigative	[8]
------------------------------------------------------------------------------------

Drug(s) Targeting Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[9]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[10]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[11]
Tiazofurin	DM5JWV9	Solid tumour/cancer	2A00-2F9Z	Approved	[12]
Mizoribine	DMW6F0S	Transplant rejection	NE84	Approved	[11]
Viramidine	DMJFNR9	Hepatitis C virus infection	1E51.1	Phase 3	[13]
VX-148	DML32R8	Psoriasis vulgaris	EA90	Patented	[14]
PMID28074661-Compound-US20100022547C81	DMM9E1U	N. A.	N. A.	Patented	[3]
PMID28074661-Compound-US20120264760C80	DM75QVW	N. A.	N. A.	Patented	[3]
Carbamide derivative 9	DMY06VC	N. A.	N. A.	Patented	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Inosine-5'-monophosphate dehydrogenase (IMPDH)	TTCAQMW	NOUNIPROTAC	Inhibitor	[2]
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)	TTL7C8Q	IMDH1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00493441) AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer. U.S. National Institutes of Health.
2	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96.
3	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
4	Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9.
5	Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8.
6	The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock. 2009 Sep;32(3):258-62.
7	US patent application no. 2010,0092,479, Compositions and methods for treatment of viral diseases.
8	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2625).
9	Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
10	Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
11	VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
12	In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
13	Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
14	Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7.